A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Gemcitabine; Sunitinib

Criteria

Inclusion Criteria:

• Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists

• Patient has good performance status (ECOG 0 or 1)

Exclusion Criteria:

• Prior treatment with either gemcitabine or SU011248

• Hypertension that cannot be controlled by medications